Table 5. Stratified analysis comparing hepatocellular carcinoma patients with CA19-9 ≥100 vs. <100 U/ml.
| Factor | HR | 95% CI | P value |
|---|---|---|---|
| Child–Pugh class: A | 1.37 | 0.56–3.37 | 0.48 |
| Child–Pugh class: B | 5.67 | 2.24–14.34 | <0.001 |
| Within Milan criteria | 2.49 | 0.48–12.97 | 0.27 |
| Outside Milan criteria | 2.04 | 1.09–3.81 | 0.02 |
| BCLC Stage: 0 + A | 1.57 | 0.33–7.39 | 0.32 |
| BCLC Stage: B + C | 2.84 | 1.50–5.41 | 0.001 |
| AFP (ng/ml): <47 (median) | 3.65 | 1.42–9.34 | 0.007 |
| AFP (ng/ml): ≥47 (median) | 2.15 | 1.02–4.56 | 0.04 |
| AFP (ng/ml): <20 | 6.15 | 2.10–18.03 | 0.0009 |
| AFP (ng/ml): ≥20 | 1.79 | 0.88–3.61 | 0.11 |
| AFP (ng/ml): <1000 | 2.18 | 1.01–4.68 | 0.04 |
| AFP (ng/ml): ≥1000 | 3.23 | 1.23–8.48 | 0.02 |
AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; HR, hazard ratio.